Sana Biotechnology, Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Sana Biotechnology, Inc. (SANA) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -0.04% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-03-03
- Sana Biotechnology, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was -0.04%.
- Sana Biotechnology, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -1.12%.
- Sana Biotechnology, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was -1.27%.
- Sana Biotechnology, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was -1.39%, a 237.62% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month |
|---|---|
| 2025-12-31 | -0.04% 10-K · filed 2026-03-03 |
| 2024-12-31 | -1.12% 10-K · filed 2026-03-03 |
| 2023-12-31 | -1.27% 10-K · filed 2026-03-03 |
| 2022-12-31 | -1.39% 10-K · filed 2025-03-17 |
| 2021-12-31 | 1.01% 10-K · filed 2024-02-29 |
| 2020-12-31 | -1.32% 10-K · filed 2023-03-16 |
| 2019-12-31 | -1.50% 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |